Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 19.19 as of 2026-10-06T15:17:12.917Z.
Consensus retrieved: 2026-10-06T12:26:45.840Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:17:12.917Z.
Quote observation: 2026-10-06T15:15:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16db4d612901c442e19fcf3bc9e492c9917e5a2542fad034f02ad0aea7e3a647
Forward PE Ratio (19.19) = Dated Quote Price ($90.65) / Consensus Forward EPS ($4.72)
FORWARD PE RATIO
19.19
SECTOR MEDIAN · HEALTHCARE
19.19
median of 165 covered companies
CURRENT VS SECTOR MEDIAN
0.00%
vs the sector median at left
HealthEquity, Inc.
Market Cap
$7.58B
Forward PE Ratio
19.19
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| HealthEquity, Inc. (HQY) | $7.58B | 19.19 |
| Hinge Health, Inc. (HNGE)vs › | $7.53B | 41.99 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.70B | N/A |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.38B | N/A |
| Alkermes plc (ALKS)vs › | $7.04B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $8.12B | 247.61 |
| Immunovant, Inc. (IMVT)vs › | $6.73B | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.45B | 17.07 |
| Chemed Corporation (CHE)vs › | $6.66B | 19.99 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.59B | N/A |
Trailing P/E
32.7
reported TTM EPS
Forward P/E
19.2
consensus EPS · fiscal year ending 2027-01-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.72 implies +70.4% EPS growth vs the reported trailing $2.77.
At the dated quote price of $90.65, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-01-31 | $4.72 | $4.70 – $4.76 | 10 | 19.2x |
| 2028-01-31 | $5.50 | $5.28 – $5.88 | 10 | 16.5x |
| 2029-01-31 | $5.98 | $5.38 – $6.42 | 4 | 15.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
